Today's Daily Dose brings you news about Alnylam's upcoming events; Celgene's blockbuster acquisition; Galapagos' osteoarthritis trial data; preliminary Q4 revenue results of Vanda, MiMedx, and Ultragenyx's phase 1/2 study data of DTX301 for the treatment of ornithine transcarbamylase deficiency.
from RTT - Biotech http://ift.tt/2m8n14O
via IFTTT
No comments:
Post a Comment